ArticleJournal of fluorescence2026
Smart Fluorescence-Responsive Polymer Hybrid Nanoparticles for Ferroptosis-Associated Therapy and Pathological Ion Detection in OSCC Cells.
Article in Journal of fluorescence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) remains a challenging malignancy due to poor drug efficacy and adverse effects. Resveratrol (RV) shows anti-OSCC potential but suffers from low solubility and bioavailability. To address this, a multifunctional polymer hybrid nanoparticle-poly(lactic-co-glycolic acid) (PLGA) modified with compound 1 and 4-(trimethoxysilyl)butanoic acid (TMSBA), and co-loaded with compound 2 and resveratrol (RV) (1-PLGA-TMSBA@2@RV)-was developed for fluorescence-responsive ferroptosis-associated therapy and pathological ion detection. The material exhibited high fluorescence selectivity toward OSCC-related GSH⁻ and Fe³⁺ ions, with quenching efficiencies of 98% and 92.9%, and a GSH⁻ detection range of 10⁻⁷-10⁻² M (R² = 0.9944) and Fe³⁺ detection limit of 10⁻⁶ M. CCK-8 assays showed RV-NPs significantly inhibited CAL-27 cell proliferation, outperforming free RV (53.8%), with blank carriers demonstrating good biocompatibility. qRT-PCR revealed RV-NPs downregulated ferroptosis regulator SLC7A11 by 71.2%, suggesting a ferroptosis-mediated antitumor mechanism. This nanoplatform offers an integrated approach for enhanced OSCC therapy and real-time pathological ion detection.
Indexed as
Identifiers
41493535What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.